Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib vs gefitinib in EGFR-mutant lung adenocarcinoma (China)
CTR20131408Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of afatinib in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Boehringer Ingelheim. Started Aug 2014; status: completed.
02
Drugs
afatinib
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on CTR20131408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131408.